Mediterr J Rheumatol 2021;32(4):290-315
Tuberculosis in Children with Rheumatic Diseases on Biologic Disease-Modifying Anti-Rheumatic Drugs: A Narrative Review
Authors Information

1. Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

2. Department of Medicine, Government Medical College, Kasaragod, India

3. Arthritis and Rheumatology Clinic, Delhi, India

4. University of Florence, School of Health Science, Rheumatology Unit, Meyer Children's University Hospital, Florence, Italy

5. Department of Paediatric Rheumatology, Amrita Institute of Medical Sciences, Kochi, India

6. Bristol Royal Hospital for Children & University of Bristol, United Kingdom

7. Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

C Kavadichanda, MB Adarsh, L Gupta 

  1. Hiraki LT, Feldman CH, Marty FM, Winkelmayer WC, Guan H, Costenbader KH. Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid. Arthritis Care Res 2017 Nov;69(11):1620-6.
  2. Muhammed H, Gupta L, Zanwar AA, Misra DP, Lawrence A, Agarwal V, et al. Infections Are Leading Cause of In-Hospital Mortality in Indian Patients with Inflammatory Myopathy. J Clin Rheumatol 2019 Dec;
  3. Al-Mayouf SM, Fallatah R, Al-Twajery M, Alayed T, Alsonbul A. Outcome of children with systemic rheumatic diseases admitted to pediatric intensive care unit: An experience of a tertiary hospital. Int J Pediatr Adolesc Med 2019 Dec;6(4):142-5.
  4. TB India Report 2018: Ministry of Health and Family Welfare [Internet]. [cited 2020 Mar 27]. Available from: https://tbcindia.gov.in/showfile.php?lid=3314
  5. Gupta L, Srivastava P, Agarwal V, Aggarwal A, Able L, Misra R, et al. High incidence of Tuberculosis in SLE patients [Internet]. Conference Abstract APLAR 2015 [cited 2020 Mar 27]. Available from: https://www.researchgate.net/publication/284448018_High_incidence_of_Tuberculosis_in_SLE_patients#fullTextFileContent
  6. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011 Nov 29;31(11):1409-17.
  7. Moorthy LN, Peterson MG, Hassett AL, Lehman TJ. Burden of childhood-onset arthritis. Pediatr Rheumatol 2010 Dec 8;8(1):20-1.
  8. Hsin Y-C, Zhuang L-Z, Yeh K-W, Chang C-W, Horng J-T, Huang J-L. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan. Doherty TM, editor. PLOS ONE 2015 Jun 5;10(6):e0128768.
  9. Tuberculosis surveillance and monitoring in Europe 2016 [Internet]. [cited 2020 Mar 27]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0019/310087/TB-surveillance-report-2016-Portugal.pdf?ua=1
  10. Sartori NS, Picon P, Papke A, Neyeloff JL, da Silva Chakr RM. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment. Abu-Shakra M, editor. PLOS One. 2019 Dec 2;14(12):e0224963.
  11. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010 Mar;69(3):522-8.
  12. Machuca I, Vidal E, de la Torre-Cisneros J, Rivero-Román A. Tuberculosis en pacientes inmunodeprimidos. Enfermedades Infecc Microbiol Clínica 2018 Jun;36(6):366-74.
  13. Lee JY. Diagnosis and Treatment of Extrapulmonary Tuberculosis. Tuberc Respir Dis 2015;78(2):47.
  14. Lao M, Chen D, Wu X, Chen H, Qiu Q, Yang X, et al. Active tuberculosis in patients with systemic lupus erythematosus from Southern China: a retrospective study. Clin Rheumatol 2019 Feb 23;38(2):535-43.
  15. Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 2013 Oct 4;22(12):1286-94.
  16. Pehlivan Y, Kisacik B, Bosnak VK, Onat AM. Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis. Case Rep 2013 Jan 21;bcr2012006585–bcr2012006585.
  17. Marie I, Hachulla E, Chérin P, Hellot M-F, Herson S, Levesque H, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Care Res 2005 Apr 15;53(2):155-65.
  18. Airio A, Kauppi M, Kautiainen H, Hakala M, Kinnula V. High association of mycobacterial infections with polymyositis in a non-endemic country for tuberculosis. Ann Rheum Dis 2007 Oct 1;66(10):1404-5.
  19. Chen I-J, Tsai W-P, Wu Y-JJ, Luo S-F, Ho H-H, Liou L-B, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology 2010 Dec 1;49(12):2429-37.
  20. Hernández-Cruz B, Sifuentes-Osornio J, Ponce-de-León Rosales S, Ponce-de-León Garduño A, Díaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol 1999;17(3):289-96.
  21. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019 Aug;78(8):1025-32.
  22. Levy R, Gérard L, Kuemmerle-Deschner J, Lachmann HJ, Koné-Paut I, Cantarini L, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2015 Nov;74(11):2043-9.
  23. Ozen S, Demirkaya E, Amaryan G, Koné-Paut I, Polat A, Woo P, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis 2014 Apr;73(4):662-7.
  24. Lin PL, Plessner HL, Voitenok NN, Flynn JL. Tumor Necrosis Factor and Tuberculosis. J Investig Dermatol Symp Proc 2007 May;12(1):22-5.
  25. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 1995 Jun;2(6):561-72.
  26. Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis Infections. Microbiol Spectr 2019 Jul 5;7(4).
  27. Azfar SF, Islam N. Suppression of Mycobacterium Tuberculosis Induced Reactive Oxygen Species andTumor Necrosis Factor-Alpha Activity in Human Monocytes of Systemic LupusErythematosus Patients by Reduced Glutathione. Oman Med J 2012 Jan 16;27(1):11-9.
  28. Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-α reagents. Pediatr Rheumatol 2014 Dec 2;12(1):45.
  29. Hsin Y-C, Zhuang L-Z, Yeh K-W, Chang C-W, Horng J-T, Huang J-L. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan. Doherty TM, editor. PLOS One 2015 Jun 5;10(6):e0128768.
  30. Zhu Z, Kang Y, Lin Z, Huang Y, Lv H, Li Y. X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis. Clin Rheumatol 2015 Feb 25;34(2):397-401.
  31. GARRED P, RICHTER C, ANDERSEN ÅB, MADSEN HO, MTONI I, SVEJGAARD A, et al. Mannan‐Binding Lectin in the Sub‐Saharan HIV and Tuberculosis Epidemics. Scand J Immunol 1997 Aug 3;46(2):204-8.
  32. Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 2018 Dec 27;20(1):285.
  33. Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 2018 Dec 27;20(1):285.
  34. Kavadichanda C, Gupta L, Balan S. Survey on Tuberculosis in children on biologics for rheumatic illnesses. Indian J Rheumatol 2020;15(2):130-3.
  35. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012 Aug 13;22(4):498-508.
  36. Hassanzadeh R, France J, Bawa S. Targeted Screening for Latent TB Infection prior to Biologic Therapy to Improve Patient Safety and Reduce Costs: A Prospective Observational Study. ISRN Infect Dis 2014;2014:1-6.
  37. Hasan T, Au E, Chen S, Tong A, Wong G. Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open 2018 Sep 12;8(9):e022445.
  38. Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 2018 Dec 27;20(1):285.
  39. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. The Lancet 2006 Apr;367(9517):1173-80.
  40. Suliman S, Geldenhuys H, Johnson JL, Hughes JE, Smit E, Murphy M, et al. Bacillus Calmette–Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses. J Immunol 2016 Aug 15;197(4):1100-10.
  41. Katelaris AL, Jackson C, Southern J, Gupta RK, Drobniewski F, Lalvani A, et al. Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A Cross-sectional Analysis of a UK-Based Cohort. J Infect Dis 2020 Jan 1;221(1):146-55.
  42. Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, et al. Safety and Efficacy of Etanercept in a Cohort of Patients with Juvenile Idiopathic Arthritis Under 4 Years of Age. J Rheumatol 2012 Jun 15;39(6):1287-90.
  43. Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, et al. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin Rheumatol 2017 Aug 8;36(8):1747-55.
  44. Ayaz NA, Demirkaya E, Bilginer Y, Özçelik U, Çobanoğlu N, Kiper N, et al. Preventing tuberculosis in children receiving anti-tnf treatment. Clin Rheumatol 2010 Apr 19;29(4):389-92.
  45. Hugle B, Burgos-Vargas R, Inman RD, O’Shea F, Laxer RM, Stimec J, et al. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol 32(3):424-31.
  46. Brunelli JB, Bonfiglioli KR, Silva CA, Kozu KT, Goldenstein-Schainberg C, Bonfa E, et al. Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country. Rev Bras Reumatol Engl Ed 2017 Sep;57(5):392-6.
  47. Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 2012 Sep 26;32(9):2675-9.
  48. Zuber Z, Rutkowska-Sak L, Postępski J, Dobrzyniecka B, Opoka-Winiarska V, Kobusińska K, et al. Etanercept treatment in juvenile idiopathic arthritis: The Polish registry. Med Sci Monit 2011;17(12):SR35-42.
  49. Verazza S, Davì S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, et al. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol 2016 Dec 20;14(1):68.
  50. Isha Saini, Lesa Dawman NG and *SK K. Biologicals in Juvenile Idiopathic Arthritis. Indian Pediatr 2016;(53):260-1.
  51. Atikan BY, Cavusoglu C, Dortkardesler M, Sozeri B. Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population. Clin Rheumatol 2016 Feb 18;35(2):427-31.
  52. Aygun D, Sahin S, Adrovic A, Barut K, Cokugras H, Camcıoglu Y, et al. The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study. Clin Rheumatol 2019 Apr 17;38(4):1025-30.
  53. Mourão AF, Santos MJ, Melo Gomes JA, Martins FM, Mendonça SC, Oliveira Ramos F, et al. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology 2016 Apr;55(4):697-703.
  54. Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, et al. Efficacy and Safety of Etanercept in Patients With the Enthesitis-Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Double-Blind Study. Arthritis Rheumatol 2015 May;67(8):2240-9.
  55. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009 Sep;60(9):2794-804.
  56. Prince FHM, Twilt M, Cate R ten, van Rossum MAJ, Armbrust W, Hoppenreijs EPAH, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009 May;68(5):635-41.
  57. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010 Feb 26;62(6):1792-802.
  58. Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, et al. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. J Rheumatol 2016 Apr;43(4):816-24.
  59. Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012 Feb 12;22(1):109-15.
  60. Brunelli JB, Schmidt AR, Sallum AME, Goldenstein-Schainberg C, Bonfá E, Silva CA, et al. High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting. Mod Rheumatol 2018 Mar 4;28(2):264-70.
  61. Tarkiainen M, Tynjälä P, Vähäsalo P, Lahdenne P. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology 2015 Jul;54(7):1170-6.
  62. Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol 2014 Oct 2;33(10):1433-41.
  63. Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 2012 Dec 2;31(12):1713-21.
  64. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin S-L, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008 May;58(5):1496-504.
  65. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. N Engl J Med 2008 Aug 21;359(8):810-20.
  66. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007 Sep;56(9):3096-106.
  67. Klein A, Becker I, Minden K, Foeldvari I, Haas J, Horneff G. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry. Scand J Rheumatol 2019 Mar 4;48(2):95-104.
  68. Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011 Jan 1;50(1):189-95.
  69. Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry. Arthritis Rheumatol 2014 Sep;66(9):2580-9.
  70. Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther 2017 Dec 22;19(1):256.
  71. Sevcic K, Orban I, Brodszky V, Bazso A, Balogh Z, Poor G, et al. Experiences with tumour necrosis factor- inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology 2011 Jul 1;50(7):1337-40.
  72. Otten MH, Prince FHM, Twilt M, ten Cate R, Armbrust W, Hoppenreijs EPAH, et al. Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis — Data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010. J Rheumatol 2011 Oct;38(10):2258-63.
  73. Kearsley-Fleet L, Sampath S, McCann LJ, Baildam E, Beresford MW, Davies R, et al. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. Rheumatology 2019 Feb 1;58(2):331-5.
  74. Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F. Safety and efficacy of Rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013 Mar 19;33(3):809-13.
  75. AlE’ed A, AlSonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int 2014 Apr 12;34(4):529-33.
  76. Dale RC, Brilot F, Duffy L V., Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014 Jul 8;83(2):142-50.
  77. Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus 2015 Aug 24;24(9):966-72.
  78. Reis J, Aguiar F, Brito I. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases. Acta Reumatol Port 41(1):45-55.
  79. Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases. J Rheumatol 2015 Mar;42(3):541-6.
  80. Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 2015 Jan 12;24(1):10-7.
  81. Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol 2015 Dec;42(12):2288-95.
  82. Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol 2014 Dec 14;12(1):3.
  83. Oddis C V., Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum 2013 Feb;65(2):314-24.
  84. Eleftheriou D, Dillon MJ, Tullus K, Marks SD, Pilkington CA, Roebuck DJ, et al. Systemic Polyarteritis Nodosa in the Young: A Single-Center Experience Over Thirty-Two Years. Arthritis Rheum 2013 Sep;65(9):2476-85.
  85. Eleftheriou D, Varnier G, Dolezalova P, McMahon A-M, Al-Obaidi M, Brogan PA. Takayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the United Kingdom. Arthritis Res Ther 2015 Dec 25;17(1):36.
  86. Aeschlimann FA, Eng SWM, Sheikh S, Laxer RM, Hebert D, Noone D, et al. Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Res Ther 2017 Dec 22;19(1):255.
  87. Sahin S, Hopurcuoglu D, Bektas S, Belhan E, Adrovic A, Barut K, et al. Childhood-onset Takayasu arteritis: A 15-year experience from a tertiary referral center. Int J Rheum Dis 2019 Jan;22(1):132-9.
  88. Poddighe D, Mukusheva Z, Dauyey K, Assylbekova M. Adalimumab in the treatment of pediatric Behçet’s disease: case-based review. Rheumatol Int 2019 Jun 11;39(6):1107-12.
  89. Markomichelakis NN, Aissopou EK, Maselos S, Tugal-Tutkun I, Sfikakis PP. Biologic Treatment Options for Retinal Neovascularization in Behçet’s Disease. Ocul Immunol Inflamm 2019 Jan 2;27(1):51-7.
  90. Acar M, Sütçü M, Aktürk H, Hançerli-Torun S, Erol OB, Salman N, et al. Tuberculosis screening in pediatric patients receiving tnf-alpha inhibitor therapy. Turk J Pediatr 2017;59(5):503.
  91. Suwannamalai P, Authavekiat P, Udomsubpayakul U, Janavitayanujit S. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Int J Rheum Dis 2009 Jul;12(2):118-24.
  92. Stoll ML, Grubbs JA, Beukelman T, Mannion ML, Jester TW, Cron RQ, et al. Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study. Pediatr Rheumatol 2017 Dec 9;15(1):79.
  93. Calzada-Hernández J, Anton-López J, Bou-Torrent R, Iglesias-Jiménez E, Ricart-Campos S, Martín de Carpi J, et al. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study. Pediatr Rheumatol 2015 Dec 3;13(1):54.
  94. Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-Meunier B, Pillet P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology 2012 Oct 1;51(10):1855-9.
  95. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010 Jan;62(1):258-67.
  96. Lepore L, Paloni G, Caorsi R, Alessio M, Rigante D, Ruperto N, et al. Follow-Up and Quality of Life of Patients with Cryopyrin-Associated Periodic Syndromes Treated with Anakinra. J Pediatr. 2010 Aug;157(2):310-15.e1.
  97. Arostegui JI, Anton J, Calvo I, Robles A, Iglesias E, López-Montesinos B, et al. Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome. Arthritis Rheumatol 2017 Aug;69(8):1679-88.
  98. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004 Feb;50(2):607-12.
  99. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018 May 17;378(20):1908-19.
  100. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011 Dec 1;70(12):2095-102.
  101. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011 Mar;63(3):840-9.
  102. Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes. Arthritis Rheum 2012 Jul;64(7):2375-86.